Gero - a biotech company using AI for target and drug discovery - in a partnership with AthenaDAO, will use their platform, anticipating the identification of up to 10 novel targets for ovarian aging. Drug development would occur collaboratively with Gero. Preliminary analysis identified genetic loci potentially associated with ovarian aging independent of systemic aging. These targets hold promise for delaying menopause and reducing its health-related consequences. This builds on Gero’s previous work using this platform approach to identify drivers of aging from the UK Biobank. AthenaDAO in collaboration with Gero aims to revolutionize the treatment landscape for ovarian aging, providing therapeutic potential in a currently limited area.